Baxdrostat meets primary and all secondary endpoints in BaxHTN phase III trial in patients with uncontrolled or treatment resistant hypertension: Cambridge, UK Wednesday, July 16, ...

The largest US real-world study of BEYFORTUS (nirsevimab-alip) 50mg and 100mg Injection successfully met both of its co-primary endpoints, demonstrating that BEYFORTUS provides protection for babies ...

AstraZeneca announced that baxdrostat, a selective aldosterone synthase inhibitor, met its primary and all secondary ...

Background Restarting direct oral anticoagulants (DOACs) after a serious bleeding event in patients with atrial fibrillation ...

A study reveals that rising vaccine coverage in children is linked to reduced antibiotic prescriptions, suggesting a shift in ...

We appreciate the opportunity to address the comments by Yangfan Cheng and colleagues, and Sebastian Walsh and colleagues regarding our Article on long-term gantenerumab treatment in dominantly ...

Emerging research positions TUDCA, a bile acid compound, as a promising neuroprotective agent against Alzheimer’s, ...

Chronic obstructive pulmonary disease (COPD) affects more than 400 million people, continues to be the third cause of death ...

Topline results were announced from a phase 3 trial evaluating atogepant vs topiramate in adults with a history of 4 or more migraine days per month.

The rate of COVID-related intensive care unit (ICU) admissions was 9.2 per 1,000 person-years among patients who received a ...

Despite offering significant protection against severe COVID-19, patients with cancer, a high-risk group, showed low uptake of booster vaccinations.

The incidence of recurrent Clostridioides difficile infection was lower among at-risk patients on antibiotics for other ...